Facteurs prédictifs de succès des étudiants en première année de médecine à l’université de Parakou

Introduction: Plusieurs facteurs dont les notes obtenues au BAC peuvent influencer les performances académiques des étudiants en première année de médecine. L'objectif de cette étude était d'évaluer la relation entre les résultats des étudiants au BAC et le succès en première année de médecine. Méthodes: Nous avons réalisé une étude analytique ayant inclus l'ensemble des étudiants régulièrement inscrits en première année à la Faculté de Médecine de l'université de Parakou durant l'année académique 2010-2011. Les données concernant les notes par discipline et mention obtenue au BAC ont été collectées. Une analyse multivariée utilisant la régression logistique et la régression linéaire multiple a permis d'établir les meilleurs prédicteurs du succès et de la moyenne de l'étudiant en fin d'année. Le logiciel SPSS version 17.0 a été utilisé pour l'analyse des données et un p<0,05 a été considéré comme statistiquement significatif. Résultats: Parmi les 414 étudiants régulièrement inscrits les données de 407 ont pu être exploitées. Ils étaient âgés de 15 à 31 ans; 262 (64,4%) étaient de sexe masculin. 98 étaient admis avec un taux de succès de 23,7%. Le sexe masculin, la note obtenue en mathématiques, en sciences physiques, la moyenne au BAC et la mention étaient associés au succès en fin d'année mais en analyse multivariée seule une note en sciences physiques > 15/20 était associée au succès (OR: 2,8 [1,32-6,00]). Pour la moyenne générale obtenue en fin d'année seule une mention bien obtenue au BAC était associée (coefficient de l'erreur standard: 0,130 Bêta =0,370 et p=0,00001). Conclusion: Les meilleurs prédicateurs du succès en première année étaient une bonne moyenne en sciences physiques au BAC et une mention bien. La prise en compte de ces éléments dans le recrutement des étudiants en première année pourrait améliorer les résultats académiques.Pan African Medical Journal 2016; 2

Comparación entre pico de torque y flexibilidad de los miembros inferiores de individuos con y sin diabetes mellitus tipo 2

O objetivo deste trabalho foi comparar o pico de torque e flexibilidade dos membros inferiores de indivíduos com e sem diabetes mellitus tipo 2 (DM2). O método foi o estudo com grupos expostos e não expostos ao DM2. Foram incluídos indivíduos com diagnóstico médico de DM2, encaminhados para eletroneuromiografia, e não expostos ao DM2. Foram excluídos da pesquisa indivíduos com idade superior a 70 anos ou que, por algum motivo, não conseguiram realizar um ou dois dos testes. A amostra foi não probabilística, composta por 64 indivíduos: 34 (53,1%) expostos ao DM2 e 30 não expostos; 50 (78,1%) eram do sexo feminino, a idade média era de 60,7±7,1 anos, e o membro inferior dominante era o direito em 57 (89,1%) dos indivíduos. Comparando indivíduos com e sem diagnóstico de DM2, observou-se redução do torque de flexão à esquerda, em velocidade angular de 120° (25,94±2,26 vs. 33,79±2,4nm, p=0,027, respectivamente). Relatou-se menor valor do torque de dorsiflexão à direita, em velocidade angular de 60°, dos diabéticos em relação aos não diabéticos (10,95±0,89 vs. 13,95±0,96nm, p=0,033, respectivamente). Ao comparar indivíduos com DM2, com e sem diagnóstico de neuropatia diabética periférica (NDP), notou-se maior déficit de flexão entre os indivíduos neuropatas em comparação com não neuropatas (46,57±9,47 vs. 11,63±13,85nm, p=0,049, respectivamente). Não foram encontradas diferenças estatisticamente significativas ao comparar os grupos de expostos e não expostos ao DM2 e diabéticos neuropatas e não neuropatas.El objetivo de este trabajo fue comparar el pico de torque y la flexibilidad de los miembros inferiores de individuos con y sin diabetes mellitus tipo 2 (DM2). El método fue el estudio con grupos expuestos y no expuestos al DM2. Se incluyeron individuos con diagnóstico médico de DM2, encaminados para electroneuromiografía, y no expuestos al DM2. Se excluyeron de la investigación a individuos mayores de 70 años o que, por algún motivo, no pudieron realizar una o dos de las pruebas. La muestra fue no probabilística, compuesta por 64 individuos: 34 (53,1%) expuestos al DM2 y 30 no expuestos; 50 (78,1%) eran de sexo femenino, la edad media era de 60,7±7,1 años, y el miembro inferior dominante era el derecho en 57 (89,1%) de los individuos. En comparación con individuos con y sin diagnóstico de DM2, se observó reducción del torque de flexión a la izquierda, en velocidad angular de 120° (25,94±2,26 frente a 33,79±2,4nm, p=0,027, respectivamente). Se ha reportado un menor valor del torque de dorsiflexión a la derecha, en velocidad angular de 60°, de los diabéticos con relación a los no diabéticos (10,95±0,89 frente a 13,95±0,96nm, p=0,033, respectivamente). Al comparar individuos con DM2, con y sin diagnóstico de neuropatía diabética periférica (NDP), se notó mayor déficit de flexión entre los individuos neuropáticos en comparación con no neuropáticos (46,57±9,47 vs. 11,63±13,85nm, p=0,049, respectivamente). No se encontraron diferencias estadísticamente significativas al comparar los grupos de expuestos y no expuestos al DM2 y los diabéticos neuropáticos y no neuropáticos.To compare the muscle strength and flexibility of the lower limbs of individuals with and without T2DM. The method was a study of the types exposed and unexposed to T2DM. Individuals diagnosed with T2DM, individuals referred to electromyography, and those unexposed to T2DM were included. The exclusion criteria were: individuals over 70 years old; those who for some reason failed to complete one or both tests. The study population consisted of 64 individuals; 34 (53.1%) exposed to DM and 30 unexposed, 50 (78.1%) were female, the mean age was 60.7±7.1 and the dominant lower limb was right in 57 (89.1%) individuals. Comparing individuals with and without a diagnosis of DM, one observed a reduction in the flexion torque on the left at a 120 ° angular velocity in diabetics individuals compared with nondiabetic patients, 25.94±2.26 vs 33.79±2, 4nm, p=0.027, respectively. The reduction in dorsiflexion torque on the right, at a 60 ° angular velocity was observed in diabetics compared with nondiabetic patients, 10.95±0.89 vs. 13.95±0.96nm, p=0.033, respectively. When comparing diabetic individuals with and without a diagnosis of PDN, one observed a greater flexion deficit among neuropathic individuals when compared with non-neuropathic individuals, 46.57±9.47 vs 11.63±13.85nm, p=0.049, respectively. No statistically significant differences were found when comparing groups exposed and unexposed to T2DM, and neuropathic and non-neuropathic diabetics

Reproducibility of left ventricular mass by echocardiogram in the ELSA-Brasil

Fundamento: A ecocardiografia, apesar de não invasiva e de relativo baixo custo, tem na variabilidade de medidas repetidas um dos principais limitantes a sua utilização em estudos epidemiológicos. Objetivo: Avaliar a reprodutibilidade da massa ventricular esquerda obtida em centros de investigação (on-line) com aquela obtida em centro de leitura (off-line) e entre medidas realizadas por diferentes avaliadores no centro de leitura. Método: Ecocardiografistas dos seis centros de investigação do ELSA-Brasil mediram on-line a massa ventricular esquerda e outras medidas ecocardiográficas de 124 exames antes de enviá-los ao centro de leitura, onde foram lidos off-line de acordo com o protocolo do estudo. Metade desses exames foi medida de forma cega por um segundo leitor. Resultados: Dos 124 exames, cinco (4%) foram considerados não mensuráveis. Dos 119 restantes, 72 (61%) eram de mulheres, com idade média de 50,2 ± 7,0 anos, sendo apenas dois exames com alteração estrutural cardíaca. Em 110 (92,4%) dos exames, as imagens foram consideradas ótimas/boas pelo centro de leitura. Não foram observadas diferenças significativas entre as médias da massa ventricular esquerda obtidas on-line e off-line (1,29 g, IC 95% −3,60-6,19), sendo o coeficiente de correlação intraclasse de 0,79 (IC 95% 0,72-0,85). Para as medidas realizadas no centro de leitura, % 0,78-0,91). Conclusão: Não houve diferenças sistemáticas relevantes na medida da massa ventricular esquerda on-line versus off-line e a reprodutibilidade das medidas foi similar à de estudos anteriores. A realização das medidas em centros de leitura, como utilizado no ELSA-Brasil, é factível e útil em estudos clínico-epidemiológicos realizados em nosso meio.Background: Echocardiography, though non-invasive and having relatively low-cost, presents issues of variability which can limit its use in epidemiological studies. Objectives: To evaluate left ventricular mass reproducibility when assessed at acquisition (online) compared to when assessed at a reading center after electronic transmission (offline) and also when assessed by different readers at the reading center. Method: Echocardiographers from the 6 ELSA-Brasil study investigation centers measured the left ventricular mass online during the acquisition from 124 studies before transmitting to the reading center, where studies were read according to the study protocol. Half of these studies were blindly read by a second reader in the reading center. Results: From the 124 echocardiograms, 5 (4%) were considered not measurable. Among the remaining 119, 72 (61%) were women, mean age was 50.2 ± 7.0 years and 2 had structural myocardial abnormalities. Images were considered to be optimal/good by the reading center for 110 (92.4%) cases. No significant difference existed between online and offline measurements (1,29g, CI 95% −3.60-6.19), and the intraclass correlation coefficientbetween them was 0.79 (CI 95% 0.71-0.85). For images read by two readers, the intraclass correlation coefficient was 0.86 (CI 95% 0.78-0.91). Conclusion: There were no significant drifts between online and offline left ventricular mass measurements, and reproducibility was similar to that described in previous studies. Central quantitative assessment of echocardiographic studies in reading centers, as performed in the ELSA-Brasil study, is feasible and useful in clinical and epidemiological studies performed in our setting

Complete revascularization versus treatment of the culprit artery only in ST elevation myocardial infarction : a multicenter registry

Fundamento: São restritos os dados sobre o manejo e o prognóstico dos pacientes com infarto agudo do miocárdio com supradesnivelamento do segmento ST (IAMCSST) com acometimento multiarterial no Brasil, o que mostra a necessidade de investigar as estratégias de revascularização disponíveis. Objetivo: Avaliar os desfechos relacionados à revascularização completa em comparação com o tratamento da artéria culpada em pacientes multiarteriais com IAMCSST. Métodos: Foi realizada um estudo de coorte prospectiva em dois centros de hemodinâmica do Sul do Brasil, com seguimento de 1 ano após a intervenção índice. O desfecho primário foi composto de óbito cardiovascular, reinfarto ou angina recorrente e secundários acidente vascular encefálico, parada cardiorrespiratória não fatal, sangramento maior ou necessidade de reintervenção. A probabilidade de ocorrência de desfechos foi comparada entre os grupos através de regressão logística binária. Considerou-se como estatisticamente significativo o valor de probabilidade < 0,05. Resultados: Participaram 85 pacientes, com média de idade de 62±12 anos, sendo 61 (71,8%) do sexo masculino. Cinquenta e oito (68,2%) pacientes receberam a estratégia de revascularização completa e 27 (31,8%), a de revascularização incompleta. A chance de ocorrência tanto do desfecho primário quanto do secundário foi significativamente maior entre os indivíduos tratados com revascularização incompleta quando comparados com os tratados com estratégia completa [razão de chances (OR) 5,1, intervalo de confiança de 95% (IC95%) 1,6-16,1 vs. OR 5,2, IC95% 1,2-22,9, respectivamente], assim como os óbitos cardiovasculares (OR 6,4, IC95% 1,2-35,3). Conclusão: Dados deste registro regional, de dois centros do Sul do Brasil, demonstram que a estratégia de revascularização completa esteve associada à redução significativa dos desfechos primário e secundário no seguimento de 1 ano quando comparada à estratégia de revascularização incompleta.Background: Data on the management and prognosis of patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease are limited in Brazil, showing that the available revascularization strategies should be investigated. Objective: To assess the outcomes of complete revascularization versus treatment of the culprit artery only in patients with STEMI and multivessel disease. Methods: A prospective cohort study was conducted at two medical centers in southern Brazil with a 1-year follow-up after the index procedure. The primary outcome was a composite of cardiac death, reinfarction, or recurrent angina, while the secondary outcome was stroke, nonfatal cardiac arrest, major bleeding, or need for reintervention. The probability of outcomes occurring was compared between the groups using binary logistic regression. A p-value < 0.05 was considered statistically significant. Results: Eighty-five patients were included. Their mean age was 62±12 years, and 61 (71.8%) were male. Fifty-eight (68.2%) were treated with complete revascularization and 27 (31.8%) with incomplete revascularization. The chance of both the primary and secondary outcomes occurring was significantly greater among patients treated with incomplete revascularization when compared to those treated with complete revascularization (odds ratio [OR] 5.1, 95% confidence interval [CI] 1.6-16.1 vs. OR 5.2, 95% CI 1.2-22.9, respectively), as well as cardiac death (OR 6.4, 95% CI 1.2-35.3). Conclusion: Registry data from two centers in southern Brazil demonstrate that the complete revascularization strategy is associated with a significant reduction in primary and secondary outcomes in a 1-year follow-up when compared to the incomplete revascularization strategy

Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection:An Analysis of the DARE-19 Randomized Controlled Trial

Background and objectives: Patients who were hospitalized with coronavirus disease 2019 (COVID-19) infection are at high risk of AKI and KRT, especially in the presence of CKD. The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial showed that in patients hospitalized with COVID-19, treatment with dapagliflozin versus placebo resulted in numerically fewer participants who experienced organ failure or death, although these differences were not statistically significant. We performed a secondary analysis of the DARE-19 trial to determine the efficacy and safety of dapagliflozin on kidney outcomes in the overall population and in prespecified subgroups of participants defined by baseline eGFR. Design, setting, participants, & measurements: The DARE-19 trial randomized 1250 patients who were hospitalized (231 [18%] had eGFR <60 ml/min per 1.73 m2) with COVID-19 and cardiometabolic risk factors to dapagliflozin or placebo. Dual primary outcomes (time to new or worsened organ dysfunction or death, and a hierarchical composite end point of recovery [change in clinical status by day 30]), and the key secondary kidney outcome (composite of AKI, KRT, or death), and safety were assessed in participants with baseline eGFR <60 and ≥60 ml/min per 1.73 m2. Results: The effect of dapagliflozin versus placebo on the primary prevention outcome (hazard ratio, 0.80; 95% confidence interval, 0.58 to 1.10), primary recovery outcome (win ratio, 1.09; 95% confidence interval, 0.97 to 1.22), and the composite kidney outcome (hazard ratio, 0.74; 95% confidence interval, 0.50 to 1.07) were consistent across eGFR subgroups (P for interaction: 0.98, 0.67, and 0.44, respectively). The effects of dapagliflozin on AKI were also similar in participants with eGFR <60 ml/min per 1.73 m2 (hazard ratio, 0.71; 95% confidence interval, 0.29 to 1.77) and ≥60 ml/min per 1.73 m2 (hazard ratio, 0.69; 95% confidence interval, 0.37 to 1.29). Dapagliflozin was well tolerated in participants with eGFR <60 and ≥60 ml/min per 1.73 m2. Conclusions: The effects of dapagliflozin on primary and secondary outcomes in hospitalized participants with COVID-19 were consistent in those with eGFR below/above 60 ml/min per 1.73 m2. Dapagliflozin was well tolerated and did not increase the risk of AKI in participants with eGFR below or above 60 ml/min per 1.73 m2

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure &lt; 100 mmHg (n = 1127), estimated glomerular filtration rate &lt; 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Reprodutibilidade de medidas ecocardiográficas da massa ventricular esquerda no Estudo Longitudinal da Saúde do Adulto, ELSA Brasil

Introdução: A hipertrofia ventricular esquerda é importante preditor de eventos cardiovasculares. A ecocardiografia é o procedimento não-invasivo de menor custo para realização das medidas necessárias para a estimativa da massa ventricular esquerda (MVE). Objetivo: Avaliar a reprodutibilidade da MVE avaliada localmente (em centros de aquisição – online) com aquela obtida em Centro de Leitura (offline) e, também, entre medidas realizadas por diferentes avaliadores no Centro de Leitura, no Estudo Longitudinal da Saúde do Adulto. Método: Exames contendo 3 ciclos cardíacos, realizados em 124 indivíduos, nos 6 centros de aquisição, foram transmitidos ao Centro de Leitura (CL) via sistema DICOM. Medidas foram realizadas no modo bidimensional localmente e no CL. Uma amostra desses exames (n=68) foi também lida por um segundo leitor no CL. Resultados: Dos 124 exames, 5 foram considerados não mensuráveis (4%). Dos 119 restantes, 72 (61%) eram mulheres, a idade média de 50,2 ± 7,0 anos, sendo apenas 2 com diagnóstico de miocardiopatia. As imagens foram consideradas ótimas/boas pelos centros de aquisição em 115 (96,6%) dos exames e pelo CL em 110 (92,4%). Não foram observadas diferenças significativas entre as médias da MVE obtidas online e offline (1,29g, IC 95% -3,60 – 6,19), sendo o coeficiente de correlação intraclasse (CCI) de 0,79 (IC 95% 0,72 – 0,85). Em relação à reprodutibilidade de medidas realizadas no CL por diferentes avaliadores, a diferença média da MVE foi de -10,50g (IC 95% -16,40 – -4,60) e o CCI foi de 0,86 (IC 95% 0,78 – 0,91). Conclusão: Não havendo diferença significativa entre as avaliações online e offline da MVE, e sendo o coeficiente de correlação intraclasse bastante bom e próximo ao observado na avaliação da variabilidade interobservador estimado no CL, é possível considerar como confiáveis as leituras offline.Background: left ventricular hypertrophy is an important predictor of cardiovascular events. Echocardiography is the least expensive non-invasive procedure that allows for left ventricular mass (LVM) assessment. Objectives: to evaluate LVM reproducibility assessed locally (acquisition centers – online) compared to that assessed at a reading center (offline) and also between evaluations performed by different readers at the reading center, among participants on the Estudo Longitudinal de Saúde do Adulto. Method: an image loop corresponding to three cardiac cycles, performed on 124 subjects, at the six acquisition centers were recorded in the DICOM format and transmitted to the reading center. Measurements were performed over bidimensional mode images locally and at the reading center. A subsample (n=68) was also measured by a second reader at the reading center. Results: Among 124 echocardiograms, 5 (4%) were considered not measurable. Among the 119 remaining, 72 (61%) were women, mean age was 50.2 ± 7.0 years and 2 were diagnosed with myocardiopathy. Images were considered to be optimal/good quality by the acquisition center on 115 (96.6%) and by the reading center on 110 (92.4%). There was no significant difference between online and offline measurements (1.29g, CI 95% -3.60 – 6.19) and intraclass correlation coefficient (ICC) between them was 0.79 (CI 95% 0.72 – 0.85). Regarding images read by two readers at the reading center, mean LVM difference was -10.50g (CI 95% -16.40 – -4.60) and the ICC was 0.86 (CI 95% 0.78 – 0.91). Conclusion: Since there was no significant difference between online and offline LVM measurements and the ICC between them were close to that observed between different measurements performed at the reading center, offline measurements were considered reliable

Efetividade e custo do tratamento invasivo da estenose valvar aórtica

O expressivo número de brasileiros que necessitam correção anatômica da estenose valvar aórtica acentuada e que não realizam cirurgia de substituição valvar devido ao risco proibitivo justifica a necessidade de investigação, tanto da efetividade no cenário clínico real quanto dos custos impostos ao Sistema Único de Saúde e aos planos de saúde suplementar brasileiros pela incorporação do implante transcateter de valva aórtica, que tem se demonstrado efetivo mas oneroso, internacionalmente. No primeiro artigo da tese, avaliaram-se os desfechos intra-hospitalares, a sobrevida e o reembolso pela internação hospitalar de 41 pacientes com idade média de 78,7 ± 6,3 anos, estenose valvar aórtica acentuada, com recusa cirúrgica e decisão multidisciplinar por tratamento transcateter entre outubro de 2010 e outubro de 2015. Os sujeitos foram seguidos prospectivamente por um período mediano de 15,2 (4,5 – 25,6) meses e a sobrevida estimada em 1 e 2 anos foi de 73,2% e 64,1%, respectivamente. Identificou-se que hipertensão pulmonar e revascularização miocárdica cirúrgica prévia estavam independentemente associadas à menor sobrevida. O valor mediano reembolsado pelos pacientes atendidos pelo Sistema Único de Saúde foi R$108.634,34 (101.051,05 – 127.255,27) e R$ 115.126,77 (94.603,21 – 132.603,01) para aqueles internados por planos de saúde suplementar ou particulares, sendo o respectivo valor mediano reembolsado pela prótese valvar de R$82.000,00 (82.000,00 – 95.450,00) e 84.050,00 (75.000,00 – 92.400,00). Em um grupo de 585 procedimentos de troca valvar aórtica cirúrgica em indivíduos com idade ≥ 60 anos, realizados entre janeiro de 2010 e dezembro de 2015 na mesma instituição, a mortalidade intra-hospitalar estava associada à idade e foi de 5,9$ 14.035,96 (11.956,11 – 16.644,90) para os internados pelo Sistema único de Saúde e R$20.273,97 (15.358.03 – 32.815,49) pelos planos de saúde suplementar ou particulares. No segundo artigo da tese, identificou-se que do total de 819 pacientes consecutivamente incluídos no Registro Brasileiro de Implante de Bioprótese Aórtica por Cateter entre janeiro de 2008 e outubro de 2015, 15 (1,8$ 108,634.34 (101,051.05 - 127,255.27) and by supplementary health plans was R$115,126.77 (94,603.21 - 132,603.01). The respective median values reimbursed for the valve prosthesis was R$ 82,000.00 (82,000.00 - 95,450.00) and 84,050.00 (75,000.00 - 92,400.00). In a group of 585 surgical aortic valve replacement procedures in subjects aged ≥ 60 years, performed between January 2010 and December 2015 in the same institution, in-hospital mortality was associated with age and was 5.9% in those with age between 60 and 70 years, 10.8% between 70 and 80 years and 22.2% in ≥ 80 years. The median reimbursement was R$14,035.96 (11,956.11 - 16,644.90) for those hospitalized by the Public Health System and R$ 20,273.97 (15,358.03 - 32,815.49) by supplementary or private health plans. In the second article of the thesis, it was identified that of the total of 819 patients consecutively included in the Brazilian Registry of Aortic Bioprosthesis Implantation by Catheter (RIBAC) between January 2008 and October 2015, 15 (1.8%) suffered perforation of the left ventricle. Patients with perforation were older (85.4 ± 6.3 vs. 81.5 ± 7.3 years, p=0.038), predominantly women (80.0% vs. 50.5%, p=0.024), had a higher ejection fraction (67.3 ± 7.8% vs. 58.6 ± 15.0%, p=0.001), lower left ventricular mass (203.9 ± 47.1g vs. 247.6 ± 78, 7g, p=0.039) and shorter distance between the aortic annulus and the left main coronary artery ostium (11.2 ± 5.4mm vs. 14.0 ± 3.3mm, p=0.034). The independent predictors of left ventricular perforation were age and ejection fraction. In the third article, a case of septal ablation was described for the treatment of asymmetric obstructive hypertrophic cardiomyopathy for posterior transcatheter aortic valve implantation, suggesting that this is a feasible strategy when these two conditions are concomitant In conclusion, the outcomes of transcatheter treatment of severe aortic stenosis in inoperable patients are compatible with those in the ideal scenario of randomized clinical trials, although they are associated with higher costs than previously estimated by expert panels. Surgical treatment, on the other hand, presented higher mortality than that idealized or reported as usual. The left ventricle hyperkinesia may favor the trauma determined by the metallic guide, positioned inside it to perform the procedure, the ejection fraction being independently associated with the chance of perforation. Furthermore, elective alcohol septal ablation, prior to transcatheter aortic valve implantation, is a feasible approach for patients with obstructive asymmetric left ventricular hypertrophy associated with aortic valve stenosis

Efetividade e custo do tratamento invasivo da estenose valvar aórtica

O expressivo número de brasileiros que necessitam correção anatômica da estenose valvar aórtica acentuada e que não realizam cirurgia de substituição valvar devido ao risco proibitivo justifica a necessidade de investigação, tanto da efetividade no cenário clínico real quanto dos custos impostos ao Sistema Único de Saúde e aos planos de saúde suplementar brasileiros pela incorporação do implante transcateter de valva aórtica, que tem se demonstrado efetivo mas oneroso, internacionalmente. No primeiro artigo da tese, avaliaram-se os desfechos intra-hospitalares, a sobrevida e o reembolso pela internação hospitalar de 41 pacientes com idade média de 78,7 ± 6,3 anos, estenose valvar aórtica acentuada, com recusa cirúrgica e decisão multidisciplinar por tratamento transcateter entre outubro de 2010 e outubro de 2015. Os sujeitos foram seguidos prospectivamente por um período mediano de 15,2 (4,5 – 25,6) meses e a sobrevida estimada em 1 e 2 anos foi de 73,2% e 64,1%, respectivamente. Identificou-se que hipertensão pulmonar e revascularização miocárdica cirúrgica prévia estavam independentemente associadas à menor sobrevida. O valor mediano reembolsado pelos pacientes atendidos pelo Sistema Único de Saúde foi R$108.634,34 (101.051,05 – 127.255,27) e R$ 115.126,77 (94.603,21 – 132.603,01) para aqueles internados por planos de saúde suplementar ou particulares, sendo o respectivo valor mediano reembolsado pela prótese valvar de R$82.000,00 (82.000,00 – 95.450,00) e 84.050,00 (75.000,00 – 92.400,00). Em um grupo de 585 procedimentos de troca valvar aórtica cirúrgica em indivíduos com idade ≥ 60 anos, realizados entre janeiro de 2010 e dezembro de 2015 na mesma instituição, a mortalidade intra-hospitalar estava associada à idade e foi de 5,9$ 14.035,96 (11.956,11 – 16.644,90) para os internados pelo Sistema único de Saúde e R$20.273,97 (15.358.03 – 32.815,49) pelos planos de saúde suplementar ou particulares. No segundo artigo da tese, identificou-se que do total de 819 pacientes consecutivamente incluídos no Registro Brasileiro de Implante de Bioprótese Aórtica por Cateter entre janeiro de 2008 e outubro de 2015, 15 (1,8$ 108,634.34 (101,051.05 - 127,255.27) and by supplementary health plans was R$115,126.77 (94,603.21 - 132,603.01). The respective median values reimbursed for the valve prosthesis was R$ 82,000.00 (82,000.00 - 95,450.00) and 84,050.00 (75,000.00 - 92,400.00). In a group of 585 surgical aortic valve replacement procedures in subjects aged ≥ 60 years, performed between January 2010 and December 2015 in the same institution, in-hospital mortality was associated with age and was 5.9% in those with age between 60 and 70 years, 10.8% between 70 and 80 years and 22.2% in ≥ 80 years. The median reimbursement was R$14,035.96 (11,956.11 - 16,644.90) for those hospitalized by the Public Health System and R$ 20,273.97 (15,358.03 - 32,815.49) by supplementary or private health plans. In the second article of the thesis, it was identified that of the total of 819 patients consecutively included in the Brazilian Registry of Aortic Bioprosthesis Implantation by Catheter (RIBAC) between January 2008 and October 2015, 15 (1.8%) suffered perforation of the left ventricle. Patients with perforation were older (85.4 ± 6.3 vs. 81.5 ± 7.3 years, p=0.038), predominantly women (80.0% vs. 50.5%, p=0.024), had a higher ejection fraction (67.3 ± 7.8% vs. 58.6 ± 15.0%, p=0.001), lower left ventricular mass (203.9 ± 47.1g vs. 247.6 ± 78, 7g, p=0.039) and shorter distance between the aortic annulus and the left main coronary artery ostium (11.2 ± 5.4mm vs. 14.0 ± 3.3mm, p=0.034). The independent predictors of left ventricular perforation were age and ejection fraction. In the third article, a case of septal ablation was described for the treatment of asymmetric obstructive hypertrophic cardiomyopathy for posterior transcatheter aortic valve implantation, suggesting that this is a feasible strategy when these two conditions are concomitant In conclusion, the outcomes of transcatheter treatment of severe aortic stenosis in inoperable patients are compatible with those in the ideal scenario of randomized clinical trials, although they are associated with higher costs than previously estimated by expert panels. Surgical treatment, on the other hand, presented higher mortality than that idealized or reported as usual. The left ventricle hyperkinesia may favor the trauma determined by the metallic guide, positioned inside it to perform the procedure, the ejection fraction being independently associated with the chance of perforation. Furthermore, elective alcohol septal ablation, prior to transcatheter aortic valve implantation, is a feasible approach for patients with obstructive asymmetric left ventricular hypertrophy associated with aortic valve stenosis